PT-141, also widely known as Bremelanotide, is a synthetic cyclic heptapeptide and a structural analogue of alpha-melanocyte stimulating hormone (α-MSH). It was originally discovered as an active metabolite of Melanotan II, modified to minimize melanin-stimulating activity while retaining potent affinity toward central melanocortin receptors. Unlike compounds that only work on peripheral blood vessels, PT-141 mainly targets melanocortin 3 receptors (MC3R) and melanocortin 4 receptors (MC4R) expressed within the hypothalamus and limbic regions of the central nervous system, making it a valuable research reagent for neuroendocrine and behavioural pathway studies.

In preclinical laboratory investigations, activation of MC4R and MC3R by PT-141 modulates multiple downstream signalling cascades related to neuroendocrine regulation, reward circuitry and autonomic nervous system response. Research models explore its function in regulating sexual behavioural responses, and related studies also extend to the exploration of energy homeostasis, appetite control, inflammatory signalling and central stress regulation. Its unique central mode of action differentiates it from peripheral vasoactive agents, providing researchers with a distinct tool to dissect melanocortin receptor physiology and related brain circuits.

This research-grade cyclic peptide is manufactured using advanced solid-phase peptide synthesis. After crude peptide synthesis, the material undergoes preparative reversed-phase HPLC purification, sterile filtration and vacuum lyophilization to form stable dry lyophilized powder. Cyclic lactam bridge structure enhances peptide resistance against enzymatic degradation compared with linear peptides. Every production batch is subjected to comprehensive quality control tests, including HPLC purity analysis, mass spectrometry identity verification, residual moisture testing, endotoxin assay and residual solvent inspection, to guarantee consistency and reliability for in vitro cell assays and animal model experiments. PT-141 powder is relatively stable under recommended frozen storage, but high temperature, prolonged light exposure and repeated freeze-thaw cycles can damage the cyclic structure, reduce receptor binding activity and generate peptide impurities.